Abstract
Objectives To determine whether fetal overgrowth preceded the diagnosis of GDM, and to quantify the inter-relationships between fetal overgrowth, GDM and maternal obesity.
Research Design and Methods
We conducted a prospective cohort study of unselected nulliparous women, and performed ultrasonic measurement of the fetal abdominal circumference (AC) and head circumference (HC) at 20 and 28 wkGA.
Exposures were diagnosis of GDM ≥28 wkGA and maternal obesity. The risk of AC >90 th and HC:AC ratio <10 th percentile were modelled using log-binomial regression, adjusted for maternal characteristics.
Results 171 (4.2%) of 4069 women were diagnosed with GDM at ≥28 wkGA. There was no association between fetal biometry at 20 wkGA and subsequent maternal diagnosis of GDM. However, at 28 wkGA, there was an increased risk ( Fetal AC >90 th percentile at 28 weeks was associated with ~4-fold risk of being large for gestational age at birth.
Conclusions Diagnosis of GDM is preceded by excessive growth of the fetal AC between 20 and 28 wkGA, and its effects on fetal growth are additive with the effects of maternal obesity.
Gestational diabetes mellitus (GDM) is one of the most common acquired medical disorders of pregnancy 1 and the major complication of GDM is excessive fetal growth. Low and middle income countries have a similar prevalence of GDM compared to high income countries, although the prevalence is particularly high in Vietnam, India, Bangladesh and Sri Lanka. 2 Pregnancies affected by GDM carry an increased risk of adverse outcome for the mother and the offspring in the short term 1;3;4 and the offspring are at increased risk of childhood obesity in the long term. 4 Large scale randomized controlled trials have confirmed that screening and treatment for GDM is associated with improved short term outcomes 5;6 but have failed to show reduced rates of childhood obesity. 7;8 Current guidelines recommend screening women for GDM between 24 to 28 weeks of gestational age (wkGA). 1;3 In practice, many units screen at around 28 wkGA. The aims of the present analysis were (1) to determine whether the onset of fetal over-growth among women subsequently diagnosed with GDM preceded the normal time of screening for the condition, and (2) to determine the inter-relationships between fetal over-growth, GDM and maternal obesity.
Methods

Design
The Pregnancy Outcome Prediction study was conducted at the Rosie Hospital, Cambridge (UK) and has been previously described in detail. 
Analysis of fetal growth
The conduct and descriptive data of the research ultrasounds are described in detail elsewhere.
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In brief, gestational dating was performed using ultrasound, and 99.5% of these examinations were performed prior to 15 wkGA. The current analysis focuses on the results of fetal biometry at 20 and 28 wkGA. All scans were performed on a Voluson i (GE, Fairfield CT, USA). The data from the 20 wkGA scan were from the routine anomaly scan offered to all women, and these results were revealed to the women and clinical team. The data from the 28 wkGA scan were fetal biometry performed for the purposes of research, and these results were blinded. The fetal head circumference (HC) and abdominal circumference (AC) were measured using the ellipse function on the machine at the standard anatomical sites.
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We have previously shown that these measurements have low inter-observer variability.
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To allow for minor variations in the exact timing of the 20 and 28 wkGA ultrasound scans, all fetal biometry was expressed as gestational age adjusted standard deviation scores (z scores), using the distribution of the measurements within the dataset.
The AC growth velocity was quantified as the difference between the AC z score at 28 wkGA and the AC z score at 20 wkGA. This approach accounts for nonlinear changes and the increasing variability of biometric measurements by gestational age, and makes different measurements from different gestational ages comparable. Z scores for HC, AC and AC growth velocity were categorised into deciles, using the distribution within the study cohort. The highest decile of AC and AC growth velocity and the lowest decile of HC:AC ratio were defined as abnormal. Sex and gestational age corrected birth weight percentiles and z scores were calculated using a population-based UK reference.
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Definitions
Maternal age was defined as age at recruitment. Body mass index (BMI) was calculated using each woman's measured height and their measured weight on the day of their booking scan. Maternal obesity was defined as BMI ≥30kg/m 2 . Maternal weight gain was defined as the difference in measured weight at the time of the 28 wkGA scan and the booking scan. Maternal ethnicity was defined by self-report in a questionnaire administered at the 20 wkGA scan. Large for gestational age (LGA) was defined as a sex and gestational age specific birth weight percentile >90 th .
Screening and diagnosis of GDM
All pregnant women were offered screening at the first antenatal booking visit with a random plasma glucose. Women with random glucose >7.0mmol/l (>126mg/dl) were offered a 75g oral glucose tolerance test (OGTT). Women were screened again at ~28 wkGA, firstly with a 50g glucose challenge test (GCT), followed by a 75g OGTT if the GCT was >7.7mmol/l (>139mg/dl), as previously described. 15 Screening for GDM was usually performed on the same day as the 28 week ultrasound scan, and GDM diagnosis was made shortly after that. Uptake of the GCT was >85% (the exact proportion could not be calculated as some tests took place in primary care). home testing using a glucometer, with fasting and 1-hour post-prandial measurements made four times per day. All women diagnosed with GDM were offered a post-partum 2 hour, 75g fasting OGTT to exclude any ongoing glycaemic dysregulation (impaired fasting hyperglycaemia, impaired glucose tolerance or type 2 diabetes mellitus). This allowed us to identify women who also had abnormal glucose tolerance outside pregnancy and, therefore, had non-gestational glycaemic dysregulation.
Exclusion criteria
We excluded women who withdrew from the study, who were lost to follow-up, who failed to attend the 20 or 28 wkGA scan, who had pre-existing diabetes or had GDM diagnosed prior to 28 wkGA, or had missing data on GDM or BMI. The women with GDM who could not be confirmed to have a normal post-partum OGTT were included in the main analysis and the effect of excluding them was assessed in a sensitivity analysis.
Statistical Analysis
Numerical data were compared using a two-sample Wilcoxon rank-sum test, and categorical data were compared using a Pearson Chi-square test with test for trend, as appropriate. The associations between the combination of GDM and obesity and the indicators of abnormal fetal growth were modelled using log-binomial regression to obtain adjusted relative risks. The relative risk of AC in the top decile at 28wkGA associated with subsequent GDM was estimated in the whole study group and stratified by maternal obesity, the treatment used, the diagnostic criteria employed, and confined to women with a normal post-partum OGTT. Non-linearity was assessed using fractional polynomials and interactions were tested using the likelihood ratio test. Missing covariate data were imputed using chained equations.
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All analyses were adjusted for the year of the 28 wkGA scan to take into account any temporal changes in the incidence, screening, diagnosis or treatment of GDM.
Analyses were performed with and without adjustment for maternal age, height, ethnicity, weight gain and BMI, as appropriate. Finally, the relative risk of LGA at birth associated with the indicators of abnormal fetal growth was estimated in the group of women who were obese and/or had GDM diagnosed at ≥28 wkGA. All analyses used Stata version 14.0.
Results
Among 4,512 recruited women, a total of 4,305 attended for their 28 wkGA scan (see Sovio et al, 10 for flow diagram). Of these, 7 withdrew, 6 failed to attend their 20 wkGA scan, 188 delivered elsewhere, 14 women had pre-existing diabetes, 17 women had GDM diagnosed prior to 28 wkGA and 7 women had missing data on GDM or BMI. A total of 236 (5.5%) of these women had one or more of the exclusion criteria, leaving a study group of 4,069 among whom 171 (4.2%) had a diagnosis of GDM ≥28 wkGA.
Women who subsequently developed GDM were older, shorter, more likely to be obese, gained slightly less weight, and were more likely to have induced labour and caesarean delivery (Table 1) . Their babies were born slightly smaller, but had higher birth weight z scores and a higher proportion of them were LGA.
At 20 wkGA, there were no significant differences in fetal biometry associated with subsequent GDM, however, the risks of AC >90 Ultrasonic fetal biometry at 28 weeks identified pregnancies at increased risk of an
LGA infant at delivery among the 672 women who were obese and/or had a diagnosis of GDM ≥28 weeks. AC growth velocity >90 all recommend that biochemical testing for GDM takes place between 24 and 28 wkGA. Practice differs internationally, and between units within countries, about whether biochemical screening is universal, using a 50g GCT, or targeted at high risk women using a 75g fasting OGTT. We use the former approach, as previously described.
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Whichever method is employed, units typically screen women at 28 wkGA. Our data suggest that fetal growth is already abnormal at 28 wkGA in women subsequently diagnosed with GDM. Consequently, our data suggest that screening prior to 28 wkGA may be one approach to improving the short and long term outcomes of pregnancies complicated by GDM. The U.S.
Preventive Services Task Force has previously observed that there is an absence of evidence regarding the effects of earlier screening. 1 Such an approach may be particularly likely to improve outcomes among obese women, as fetal growth was already abnormal by 20 wkGA among these women in the cohort. In fact, the current data indicate that any intervention aimed at reducing the risk of LGA in the infants of obese women may need to be implemented before 20 wkGA. Finally, the offspring of women with GDM are at increased risk of childhood obesity 4 but RCTs have failed to demonstrate that screening and intervention in pregnancy reduces this risk. 7;8 The current data suggest a possible explanation, namely, that screening and intervention is taking place when the effects of GDM are already manifested in the fetus. Hence, the current findings indicate that earlier screening and intervention for GDM may result in better short and long term outcomes. Testing this hypothesis would be an appropriate focus for future randomised controlled trials.
The main strengths of the current study are that it was prospective, and that ultrasonic fetal biometry was performed at 20 and 28 wkGA in a large cohort of unselected nulliparous women. Many other studies of fetal growth in both preexisting and gestational diabetes are confined to women who had a diagnosis of diabetes. 19;20 It is clearly problematic to define abnormal growth related to diabetes in the absence of data on fetal growth in non-diabetic women. Further strengths of the study are that we had detailed clinical information on the individual women. Hence, we were able to analyse the results in relation to the treatment used for GDM, and in relation to the results of re-testing of women in the post-partum period. Moreover, we had detailed information on maternal covariates, such as anthropometry, weight gain, ethnicity and age. The incidence of GDM in our cohort was consistent with UK rates of 3-5% when universal biochemical screening is performed. 21 However, the women in the cohort were mostly of white European ancestry. We did not observe any statistically significant interactions between ethnicity and the exposures, however, the numbers were small. The present study recruited women over a 4.5 year period. During this period of time, there were changes in the definition of GDM.
In the study cohort, 4.8% of the women were deemed screen positive using the modified WHO (1999) criteria whereas 3.5% screened positive using the modified IADPSG criteria. There were 54 (1.3%) women who screened positive using the modified WHO (1999) criteria but not the modified IADPSG criteria and two (<0.1%) women who had the opposite discrepancy. However, the results were virtually identical when the association was studied by year of the 28 wkGA scan. The HAPO study 22 demonstrated a continuum in the risk of LGA in relation to hyperglycaemia.
The similar findings in relation to AC comparing the modified WHO and the modified IADPSG criteria may reflect the fact that women just below a given threshold are very similar to those who lie just above it. Finally, the use of the 50g GCT approach is estimated to have a sensitivity of 74% for GDM. 23 It follows that some of the women defined as normal in the cohort may have had undiagnosed GDM.
Misclassification tends to lead to underestimates of the strength of true associations, and it is possible that the associations would have been even stronger had all women been screened using a fasting 75g OGTT.
Conclusions
Diagnosis of GDM ≥28 wkGA is preceded by excessive fetal growth between 20 and 28 wkGA. Currently, biochemical testing for GDM typically takes place at around 28 wkGA. As fetal growth is already abnormal at this stage, it is plausible that earlier screening and intervention may result in lower risks of adverse outcomes.
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